Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc



    FDA Offers Special Protocol Assessment for Reviroc

    AMSTERDAM, Dec. 19 /CNW/ - Kiadis Pharma announced today that it has
successfully completed an End of Phase II meeting for Reviroc with the U.S.
Food and Drug Administration (FDA). Reviroc is under development for
elimination of cancer cells from an autologous graft in bone marrow
transplantations for end-stage blood cancer patients. The FDA agreed that the
data from the completed phase II clinical Reviroc trial is sufficient to
support the start of a phase III study. The FDA offered Kiadis Pharma its
Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work
directly with the FDA to optimize the clinical design of the trial.
    The FDA meeting followed the successful completion of a multi centre
phase II study for Reviroc showing an improved overall survival after
autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The
phase III clinical trial design for Reviroc will focus on patients with Large
B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and
Orphan Drug Designation application with the FDA within the next few weeks.
    "We are very pleased with the outcome of the End of Phase II meeting with
the FDA and with the possibility to access the FDA's Special Protocol
Assessment program. Together with the strong support by our principal
investigators we are well prepared to design a clear path towards marketing
authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

    About Reviroc

    Reviroc is being developed as a treatment that eliminates blood cancer
cells from autologous transplants for patients with end stage blood cancer. An
autologous transplant uses the patient's own bone marrow to serve as a graft.
Bone-marrow transplants are broadly recognized as a treatment option for
patients suffering from blood cancers, such as leukemia and lymphoma. One of
the limitations of autologous bone marrow transplantations is the high relapse
rate associated with this treatment. This is often caused by the presence of
cancer cells in the transplant and the fact that the patients' own white blood
cells does not fight the cancer. Reviroc has been developed to remove residual
tumor cells from the graft.

    English release is provided by Kiadis Pharma. Equivalent translations are
from a third party.





For further information:

For further information: Kiadis Pharma B.V., Eefje Simpelaar, Director
Communications, e.simpelaar@kiadis.com, +31-208-884-815, +31-610-829-344

Organization Profile

KIADIS PHARMA B.V.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890